| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 4032 |
Provisional Schedule
| Committee meeting | 06 June 2024 |
| Expected publication | 14 August 2024 |
Project Team
| Project lead | Kate Moore |
Email enquiries
- If you have any queries please email TATeam5@nice.org.uk
| External Assessment Group | BMJ Technology Assessment Group (BMJ-TAG), BMJ |
Stakeholders
| Companies sponsors | Pfizer (fidanacogene elaparvovec) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Gene People |
| Haemophilia Society | |
| Professional groups | Royal College of Physicians |
| Comparator companies | CSL Behring (etranacogene dezaparvovec) |
| Novo Nordisk - CAU not returned, not participating | |
| Pfizer (nonacog alfa) | |
| Swedish Orphan Biovitrum (eftrenonacog alfa) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| British National Formulary | |
| Cell and Gene Therapy Catapult | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Haemophilia Scotland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 25 October 2023 | Invitation to participate |
| 17 May 2023 - 15 June 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 4032 |
| 17 May 2023 | In progress. Scoping commencing |
| 12 August 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual